In Trethera’s prior expanded access case, treatment with TRE-515 in an 87-year-old patient with advanced ALS was associated with a slowing of forced vital capacity decline from roughly 1.2% per week pre-treatment to 0.5% at three months and 0.2% at 6.5 months, with no adverse events attributed to the drug. The patient later discontinued therapy after a fall and subsequently died from pneumonia. These single-patient data are now informing a new expanded access effort at Massachusetts General Hospital to prospectively track safety, function, and biomarkers on treatment.
The company has entered a clinical collaboration with MGH to treat up to six patients with advanced ALS under an FDA Expanded Access protocol. The MGH-run program will assess safety and tolerability while measuring disease trajectory using monthly ALSFRS-R and slow vital capacity, and will collect pharmacodynamic readouts of TRE-515 pathway activity alongside established ALS biomarkers such as neurofilament light chain. TRE-515 is an oral inhibitor of deoxycytidine kinase, a nodal enzyme in the nucleoside salvage pathway implicated in inflammatory signaling, aligning the candidate with the growing focus on neuroinflammation in ALS.
Strategically, this is a fast-follow move to convert anecdotal experience into a structured, biomarker-integrated dataset without waiting for a traditional early-phase neuro trial to ramp. For a company rooted in oncology and autoimmunity, the step into ALS via expanded access suggests a capital-efficient path to de-risking mechanism and dose, leveraging MGH’s ALS infrastructure and assay capabilities. The tension is clear: small, uncontrolled cohorts can generate suggestive signals and operational learning, but they rarely change regulatory calculus in a field where the bar has tightened after recent reversals. If TRE-515’s effect is primarily immunomodulatory, demonstrating target engagement and biomarker alignment with functional slope will matter as much as nominal trends on ALSFRS-R.
For sites, the protocol concentrates activity in a high-throughput academic center, easing startup but concentrating operational burden around monthly respiratory assessments and standardized capture of ALSFRS-R. The biomarker plan will require tight chain-of-custody for NfL and specialized pharmacodynamic assays, which could challenge scale-up beyond a single center. If the program broadens to additional institutions, harmonization of sampling windows and assay platforms will be a gating factor. For sponsors and CROs, the design reflects a broader pattern of using expanded access to seed evidence and relationships ahead of randomized entry into platforms such as the HEALEY ALS trial; however, the advanced-disease population here may not mirror the earlier-stage cohorts typically prioritized in controlled studies, complicating read-through.
Regulators will largely view the dataset as hypothesis-generating. Any reduction in NfL or stabilization of respiratory decline will be useful for powering assumptions and enrichment strategies but will not obviate the need for randomized, placebo-controlled evidence or platform-based comparisons. Patients may gain near-term access in a setting with intensive monitoring, though expectations around efficacy should remain conservative given the cohort size and disease stage.
What matters next is whether TRE-515 shows consistent target engagement and a coherent biomarker-to-clinical narrative across the six patients, without emergent safety liabilities in advanced ALS. If those pieces line up, Trethera’s next decisions will likely center on moving into a multi-center, earlier-stage population with a randomized design and predefined biomarker endpoints, potentially through a platform collaboration to compress timelines. Watch for assay reproducibility, durability signals over six to twelve months, and the company’s ability to operationalize beyond a single-site hub. The risk remains that preliminary stabilization does not persist or translate outside of anecdotal contexts; the opportunity is a rapid, data-informed pivot into a controlled trial with a clear biological rationale.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
